Nine cases of chronic hand and foot eczema treated with baricitinib

Abstract

AbstractChronic hand and foot eczema (CHFE) is a common inflammatory disorder that generally lasts for over 3 months. If it is intractable to topical agents, systemic immunomodulators can be considered; however, they are not suitable for long‐term management because of their adverse effects. Baricitinib is an oral Janus kinase inhibitor that has been approved for the treatment of moderate‐to‐severe atopic dermatitis. However, its effect on CHFE has rarely been described. Herein, we report nine cases of recalcitrant CHFE that were treated with baricitinib after an inadequate response to low‐dose ciclosporin. All patients had more than moderate improvement within 2–8 weeks without serious adverse effects.